
Graves' Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Graves' Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Graves' Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy - Drugs In Development, 2022, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.
Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves' ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 5, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Graves' Ophthalmopathy Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Graves' Ophthalmopathy - Drugs In Development, 2022, provides an overview of the Graves' Ophthalmopathy (Ophthalmology) pipeline landscape.
Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves' ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications and thyroid surgery.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Graves' Ophthalmopathy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Graves' Ophthalmopathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Graves' Ophthalmopathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Graves' Ophthalmopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 4, 2, 5, 1, 3 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.
Graves' Ophthalmopathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Graves' Ophthalmopathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graves' Ophthalmopathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graves' Ophthalmopathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graves' Ophthalmopathy (Ophthalmology)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graves' Ophthalmopathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graves' Ophthalmopathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
67 Pages
- Introduction
- Global Markets Direct Report Coverage
- Graves' Ophthalmopathy – Overview
- Graves' Ophthalmopathy – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Graves' Ophthalmopathy – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Graves' Ophthalmopathy – Companies Involved in Therapeutics Development
- advanceCor GmbH
- Enceladus Pharmaceuticals BV
- Eye Bio Korea Co Ltd
- Genmab AS
- GSK plc
- HanAll Biopharma Co Ltd
- ImmunoGen Inc
- Innovent Biologics Inc
- Jiangsu Hengrui Medicine Co Ltd
- Novartis AG
- Pierre Fabre Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
- RevOpsis Therapeutics Corp
- Sling Therapeutics Inc
- Suzhou Pulekang Pharmaceutical Technology Co Ltd
- Viridian Therapeutics Inc
- Graves' Ophthalmopathy – Drug Profiles
- aflibercept – Drug Profile
- AVE-1642 – Drug Profile
- batoclimab – Drug Profile
- belimumab – Drug Profile
- Fusion Protein to Target IGF-1R and PD-L1 for Graves' Ophthalmopathy – Drug Profile
- IBI-311 – Drug Profile
- linsitinib – Drug Profile
- PHP-1003 – Drug Profile
- prednisolone sodium phosphate – Drug Profile
- RO-103 – Drug Profile
- secukinumab – Drug Profile
- Synthetic Peptides for Graves Diseases and Graves Ophthalmopathy – Drug Profile
- teprotumumab – Drug Profile
- Thyroid Eye Disease – Drug Profile
- VB-421 – Drug Profile
- VRDN-002 – Drug Profile
- VRDN-003 – Drug Profile
- vunakizumab – Drug Profile
- ZB-011 – Drug Profile
- Graves' Ophthalmopathy – Dormant Projects
- Graves' Ophthalmopathy – Product Development Milestones
- Featured News & Press Releases
- Nov 16, 2022: Horizon Therapeutics announces completion of enrollment of phase 3 clinical trial (OPTIC-J) in Japan evaluating TEPEZZA (teprotumumab-trbw) for the treatment of active thyroid eye disease (TED)
- Nov 14, 2022: Viridian announces positive data from ongoing phase 1/2 trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED)
- Oct 22, 2022: Viridian provides update on VRDN-002
- Oct 22, 2022: Viridian presents positive clinical data from ongoing VRDN-001 phase 1/2 trial in active thyroid eye disease (TED) patients during late-breaking presentations at the American Thyroid Association (ATA) 91st Annual Meeting
- Oct 22, 2022: Horizon Therapeutics to present new data on TEPEZZA (teprotumumab-trbw) and Thyroid Eye Disease (TED) at the American Thyroid Association (ATA) annual meeting
- Oct 22, 2022: New real-world analysis of TEPEZZA (teprotumumab-trbw) use indicates a small percentage of people receive a second course of treatment
- Oct 22, 2022: Viridian Therapeutics announces presentations at the American Thyroid Association 91st Annual Meeting
- Sep 29, 2022: Horizon Therapeutics completes enrollment for Phase 4 Trial of TEPEZZA (teprotumumab-trbw) in adults with chronic/low clinical activity score (CAS) Thyroid Eye Disease (TED)
- Aug 18, 2022: Innovent announces first subject dosed in phase 1 study of IBI311 (anti-IGF-1R monoclonal antibody)
- Aug 15, 2022: Viridian announces positive initial clinical data from ongoing phase 1/2 trial evaluating VRDN-001 in patients with Thyroid Eye Disease (TED)
- Jun 14, 2022: Horizon Therapeutics to highlight data and education on thyroid eye disease (TED) at the Endocrine Society (ENDO) 2022 Annual Conference
- Jun 11, 2022: Analysis of pooled data from TEPEZZA (teprotumumab-trbw) clinical trials reinforces safety profile in people with Thyroid Eye Disease (TED)
- May 16, 2022: Zenas BioPharma submits investigational New Drug Application in China for ZB001 for the treatment of thyroid eye disease
- Mar 31, 2022: ValenzaBio announces FDA clearance of investigational new drug application for VB421, an anti-IGF-1R monoclonal antibody for the treatment of thyroid eye disease
- Mar 21, 2022: Viridian Therapeutics doses first subject in first-in-human clinical trial evaluating VRDN-002, a next generation IGF-1R antibody for the treatment of thyroid eye disease
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Graves' Ophthalmopathy, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Universities/Institutes, 2022
- Table 4: Products under Development by Companies, 2022
- Table 5: Products under Development by Companies, 2022 (Contd..1)
- Table 6: Products under Development by Universities/Institutes, 2022
- Table 7: Number of Products by Stage and Target, 2022
- Table 8: Number of Products by Stage and Mechanism of Action, 2022
- Table 9: Number of Products by Stage and Route of Administration, 2022
- Table 10: Number of Products by Stage and Molecule Type, 2022
- Table 11: Graves' Ophthalmopathy – Pipeline by advanceCor GmbH, 2022
- Table 12: Graves' Ophthalmopathy – Pipeline by Enceladus Pharmaceuticals BV, 2022
- Table 13: Graves' Ophthalmopathy – Pipeline by Eye Bio Korea Co Ltd, 2022
- Table 14: Graves' Ophthalmopathy – Pipeline by Genmab AS, 2022
- Table 15: Graves' Ophthalmopathy – Pipeline by GSK plc, 2022
- Table 16: Graves' Ophthalmopathy – Pipeline by HanAll Biopharma Co Ltd, 2022
- Table 17: Graves' Ophthalmopathy – Pipeline by ImmunoGen Inc, 2022
- Table 18: Graves' Ophthalmopathy – Pipeline by Innovent Biologics Inc, 2022
- Table 19: Graves' Ophthalmopathy – Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2022
- Table 20: Graves' Ophthalmopathy – Pipeline by Novartis AG, 2022
- Table 21: Graves' Ophthalmopathy – Pipeline by Pierre Fabre Pharmaceuticals Inc, 2022
- Table 22: Graves' Ophthalmopathy – Pipeline by Regeneron Pharmaceuticals Inc, 2022
- Table 23: Graves' Ophthalmopathy – Pipeline by RevOpsis Therapeutics Corp, 2022
- Table 24: Graves' Ophthalmopathy – Pipeline by Sling Therapeutics Inc, 2022
- Table 25: Graves' Ophthalmopathy – Pipeline by Suzhou Pulekang Pharmaceutical Technology Co Ltd, 2022
- Table 26: Graves' Ophthalmopathy – Pipeline by Viridian Therapeutics Inc, 2022
- Table 27: Graves' Ophthalmopathy – Dormant Projects, 2022
- List of Figures
- Figure 1: Number of Products under Development for Graves' Ophthalmopathy, 2022
- Figure 2: Number of Products under Development by Companies, 2022
- Figure 3: Number of Products by Top 10 Targets, 2022
- Figure 4: Number of Products by Stage and Top 10 Targets, 2022
- Figure 5: Number of Products by Top 10 Mechanism of Actions, 2022
- Figure 6: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
- Figure 7: Number of Products by Top 10 Routes of Administration, 2022
- Figure 8: Number of Products by Stage and Top 10 Routes of Administration, 2022
- Figure 9: Number of Products by Molecule Types, 2022
- Figure 10: Number of Products by Stage and Molecule Types, 2022
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.